20 Posts Not To Miss From ASCO 2026: Lung Edition
Oncodaily highlights 20 key research posts from the ASCO 2026 oncology conference, focusing on advancements in lung cancer treatments. The article covers breakthroughs in targeted therapies, immunotherapy, and antibody-drug conjugates.
Why it matters
These updates represent significant progress in cancer care, directly impacting clinical treatment protocols and patient outcomes for various malignancies.
ASCO 2026 brought together the global oncology community for several days of practice-changing research, clinical discussions, and scientific updates across cancer care. Lung cancer once again had a strong presence, with important data and expert reflections covering non-small cell lung cancer, small cell lung cancer, targeted therapies, immunotherapy, antibody-drug conjugates, perioperative treatment, and emerging biomarkers.
The content is a factual summary of medical conference proceedings without political or ideological framing.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in